Stock Scorecard
Stock Summary for Halozyme Therapeutics Inc (HALO) - $71.72 as of 10/3/2025 4:07:56 PM EST
Total Score
14 out of 30
Safety Score
62 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for HALO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for HALO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for HALO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for HALO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for HALO (62 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 8 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for HALO
Financial Details for HALO
Company Overview |
|
|---|---|
| Ticker | HALO |
| Company Name | Halozyme Therapeutics Inc |
| Country | USA |
| Description | Halozyme Therapeutics, Inc. is a leading biopharmaceutical technology company based in San Diego, California, specializing in innovative drug delivery solutions that enhance the efficacy of existing therapies. With a global presence across the United States, Europe, and Asia, Halozyme leverages its proprietary ENHANZE® technology to develop subcutaneous formulations for various indications, improving patient experience and compliance. The company collaborates with major pharmaceutical partners to expand its therapeutic portfolio, positioning itself as a pivotal player in the evolving landscape of biotechnology and drug administration. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/28/2025 |
Stock Price History |
|
| Last Day Price | 71.72 |
| Price 4 Years Ago | 40.21 |
| Last Day Price Updated | 10/3/2025 4:07:56 PM EST |
| Last Day Volume | 2,656,252 |
| Average Daily Volume | 2,110,939 |
| 52-Week High | 79.50 |
| 52-Week Low | 42.01 |
| Last Price to 52 Week Low | 70.72% |
Valuation Measures |
|
| Trailing PE | 16.41 |
| Industry PE | 21.94 |
| Sector PE | 41.81 |
| 5-Year Average PE | 19.77 |
| Free Cash Flow Ratio | 135.32 |
| Industry Free Cash Flow Ratio | 14.52 |
| Sector Free Cash Flow Ratio | 30.43 |
| Current Ratio Most Recent Quarter | 8.36 |
| Total Cash Per Share | 0.53 |
| Book Value Per Share Most Recent Quarter | 2.83 |
| Price to Book Ratio | 26.34 |
| Industry Price to Book Ratio | 29.60 |
| Sector Price to Book Ratio | 32.30 |
| Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Industry Price to Sales Ratio Twelve Trailing Months | 43.64 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.26 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 116,966,000 |
| Market Capitalization | 8,388,801,520 |
| Institutional Ownership | 102.66% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 3.06% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 84.70% |
| Annual Earnings Growth | 57.71% |
| Reported EPS 12 Trailing Months | 4.37 |
| Reported EPS Past Year | 2.65 |
| Reported EPS Prior Year | 4.23 |
| Net Income Twelve Trailing Months | 557,278,000 |
| Net Income Past Year | 444,091,000 |
| Net Income Prior Year | 281,594,000 |
| Quarterly Revenue Growth YOY | 40.80% |
| 5-Year Revenue Growth | 38.95% |
| Operating Margin Twelve Trailing Months | 62.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 61,861,000 |
| Total Cash Past Year | 115,850,000 |
| Total Cash Prior Year | 118,370,000 |
| Net Cash Position Most Recent Quarter | -1,447,239,000 |
| Net Cash Position Past Year | -1,389,948,000 |
| Long Term Debt Past Year | 1,505,798,000 |
| Long Term Debt Prior Year | 1,499,248,000 |
| Total Debt Most Recent Quarter | 1,509,100,000 |
| Equity to Debt Ratio Past Year | 0.19 |
| Equity to Debt Ratio Most Recent Quarter | 0.18 |
| Total Stockholder Equity Past Year | 363,821,000 |
| Total Stockholder Equity Prior Year | 83,808,000 |
| Total Stockholder Equity Most Recent Quarter | 332,748,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 540,693,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 4.62 |
| Free Cash Flow Past Year | 468,368,000 |
| Free Cash Flow Prior Year | 373,277,000 |
Options |
|
| Put/Call Ratio | 0.16 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 1.16 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/4/2025 12:56:26 AM EST |